Ipamorelin: Growth Hormone Secretagogue Peptide Updates

Ipamorelin, a selective ghrelin mimetic pentapeptide, targets GHSR for pulsatile GH release in neuroendocrine research. From Novo Nordisk and University of Copenhagen labs.

Ipamorelin's 2024-2025 Milestones

In tilapia models, Mallikarjun Gouda at Karnatak University showed HPA axis modulation. POI management phase 2 by Michael Camilleri at Mayo Clinic reduced ileus duration.

Cisplatin weight loss mitigation in ferrets by Zengbing Lu at the Chinese University of Hong Kong yielded 8% preservation. Bone mineral increase in rats by Kerstin Malmberg at Novo Nordisk reached 5%.

Ipamorelin Mechanisms

Calcium/adrenergic insulin stimulation in European Journal of Endocrinology by Adel Ismail at Ain Shams University. Somatotroph response in Growth Hormone & IGF Research by M. Granata at the University of Turin.

GC counteraction in Growth Hormone & IGF Research by Jörgen Isgaard at the University of Gothenburg.

Ipamorelin Trajectories

Nasal pharmacokinetics in British Journal of Clinical Pharmacology by Anders R. Hansen at Novo Nordisk. Adiposity effects in Endocrinology by Jeffrey N. Miner at Lexicon Pharmaceuticals.

Links

• [Tilapia](https://pubmed.ncbi.nlm.nih.gov/38996787/)
• [POI](https://pubmed.ncbi.nlm.nih.gov/25331030/)
• [Ferrets](https://pubmed.ncbi.nlm.nih.gov/39043357/)